Melanoma Research Alliance Marks 20 Years, Sets New Priorities

The Melanoma Research Alliance was founded in 2007 at a time when melanoma research was fragmented and scientifically neglected, with few treatment options available to patients, Kauffman said. Since then, the organization has invested more than $200 million in melanoma research and supported more than 550 projects worldwide.

"We really did help, and we've helped bring about a research ecosystem that really did not exist prior to us being founded in 2007," Kauffman said.

The melanoma treatment landscape has changed substantially over that period. Kauffman pointed to 20 FDA-approved treatments for melanoma and the emergence of immunotherapy alongside targeted therapies as evidence of how far the field has progressed.

There are now 20 approved FDA treatments for melanoma patients. That's kind of unheard of in oncology. — Stephanie Kauffman

Rather than viewing MRA's approaching anniversary solely as an opportunity to reflect on that progress, Kauffman said she sees it as a chance to determine what comes next.

"When we think about anniversaries and milestones, while it's definitely a great opportunity to look back, in my mind it's the right opportunity to look forward," she said.

Gaps Remain in Treatment Response and Early Detection

Despite the expansion of available therapies, substantial treatment gaps remain. Kauffman said approximately 50% of patients with advanced melanoma still do not respond to currently available treatments.

"Unfortunately 50% of patients who have advanced melanomas still don't respond to what's in the marketplace for treatments," Kauffman said.

Understanding why some patients respond while others do not will be an important question for the field moving forward. Treatment resistance represents another challenge, with some patients initially responding well to a particular treatment before eventually experiencing disease progression.

"How does treatment resistance develop?" Kauffman said. "We'll have patients who've been on a particular treatment protocol, they're doing really, really well, and for some reason they stop responding to that treatment."

Kauffman also pointed to opportunities to improve early detection, particularly through collaboration with the dermatology community. Together, these questions reflect a broader shift toward making melanoma treatment more precise rather than simply expanding the number of available therapies.

Rare, Non-UV Melanomas Need Further Study

Rare melanoma subtypes that are not driven by UV exposure represent another area requiring continued investigation, Kauffman said. She highlighted uveal melanoma, acral melanoma, and mucosal melanoma as examples.

These melanomas arise in locations including the eye, palms and soles, and mucous membranes, creating distinct scientific questions from those surrounding UV-associated cutaneous melanoma.

"How do we need to continue to unravel the biology of something that's not there?" Kauffman said, referring to the absence of UV exposure as the driving factor in these melanomas.

Collaboration Will Shape MRA's Next Era

Kauffman's vision for MRA's next chapter also reflects her background bringing together organizations and sectors to solve complex problems. Before entering the nonprofit sector, she spent more than 16 years at Universal Studios and later held leadership roles at the Breast Cancer Research Foundation and Americares.

At MRA, she said the organization operates at the intersection of scientists, clinicians, researchers, pharmaceutical and biotechnology companies, government organizations, philanthropic funding, and patients. She highlighted relationships with organizations including the National Institutes of Health, American Academy of Dermatology, and FDA.

For Kauffman, strengthening those connections offers an opportunity to accelerate scientific discovery and ultimately improve outcomes for patients with melanoma.

"The next era of melanoma research is upon us, and I'm excited to see what we can do because we've been that launchpad," Kauffman said.

References

1. Melanoma treatment (PDQ®)–health professional version. National Cancer Institute. Updated March 14, 2025. Accessed August 18, 2026. https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq
2. Advances in melanoma and other skin cancers research. National Cancer Institute. Updated April 30, 2024. Accessed August 18, 2026. https://www.cancer.gov/types/skin/research
3. FDA approves new engineered viral immunotherapy for patients with treatment-resistant advanced melanoma. FDA. Published August 6, 2026. Accessed August 18, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma